Want to see SRRK full AI Analyst Report?
Top Page
Scholar Rock Holding
(NASDAQ:SRRK)
Select Model
Select Model
Rating:51Neutral
Price Target:
$48.00
▲(0.69% Upside)
Action:Reiterated
Date:08/06/26
SRRK scores 51 primarily due to weak financial performance (zero revenue, widening losses, and heavy cash burn with rising debt) and soft technical momentum (price below key moving averages with negative MACD). These are partially offset by a strong earnings-call outlook centered on a defined PDUFA date, dual manufacturing pathways, and stated launch readiness, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Regulatory Milestone
BLA acceptance with a fixed PDUFA date provides a near-term regulatory inflection that materially de-risks development-stage uncertainty. A defined review timeline enables concrete commercial planning, partner negotiations and capital decisions tied to a potential approval outcome over the next months.
Negative Factors
No Commercial Revenue
The company remains pre-revenue with materially widening net losses and sustained negative operating cash flow. Persistent burn without product sales makes the business structurally dependent on external financing, increasing dilution and refinancing risk if commercialization timing slips or payer uptake is slower than expected.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Milestone
BLA acceptance with a fixed PDUFA date provides a near-term regulatory inflection that materially de-risks development-stage uncertainty. A defined review timeline enables concrete commercial planning, partner negotiations and capital decisions tied to a potential approval outcome over the next months.
Read all positive factors
Scholar Rock Holding (SRRK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.44B
Dividend YieldN/A
Average Volume (3M)1.53M
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue GrowthN/A
EPS Growth-14.40%
CountryUS
Employees289
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.31
Shares Outstanding121,785,280
10 Day Avg. Volume1,038,028
30 Day Avg. Volume1,529,778
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$62.00Price Target Upside30.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.26
Revenue Forecast (FY)$6.00M
Scholar Rock Holding Business Overview & Revenue Model
Company Description
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apiteg...
How the Company Makes Money
Scholar Rock primarily generates revenue from collaboration and licensing arrangements rather than from product sales, as it is a clinical-stage company. Key revenue streams typically include (1) upfront payments received when entering into strate...
Scholar Rock Holding Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The call conveyed strong forward momentum: the BLA is accepted with a fixed PDUFA date, management has established two independent manufacturing paths (reducing single-site risk), commercial operations are launch-ready, the pipeline is advancing (Phase II OPAL recruitment, FORGE initiated, SRK-439 dosing), and the company finished the quarter with a healthy cash balance and financing optionality. Main negatives are the outstanding FDA inspection classification for Catalent Indiana (which also affects EMA timing), ongoing third-party manufacturing/regulatory timing risk, and expected payer/reimbursement friction that could delay patient access after approval. On balance, the positive regulatory progress, commercial preparedness, clinical achievements and solid cash position outweigh the operational and reimbursement risks discussed on the call.Positive Updates
BLA Accepted; PDUFA Date Set
Apitegromab BLA was accepted in April with a PDUFA date of September 30, 2026, giving a clear regulatory milestone and the company states the review is progressing well.
Negative Updates
Catalent Indiana Inspection Classification Pending
The sole approvability issue from the prior CRL related to observations from a general site inspection at Catalent Indiana; the FDA's inspection classification from the April 2026 reinspection remains pending and this uncertainty is being monitored by both the company and EMA.
Read all updates
Q2-2026 Updates
Positive
Negative
BLA Accepted; PDUFA Date Set
Apitegromab BLA was accepted in April with a PDUFA date of September 30, 2026, giving a clear regulatory milestone and the company states the review is progressing well.
Read all positive updates
Company Guidance
The company reiterated that apitegromab’s BLA (resubmitted March 30 with two fill/finish sites and accepted in April) remains under active FDA review with a September 30, 2026 PDUFA date (55 days from the call) and two independent approval paths (Catalent Indiana — inspection classification pending — and a second facility whose full data have been submitted, which currently has more commercial vials on hand than Catalent and vials staged at a third‑party packaging site); the EMA MAA currently includes Catalent and is awaiting the FDA inspection classification while discussions to add the second site are ongoing. Commercially the company says it is launch‑ready in the U.S. (covering ~140 SMA treatment centers and ~2,600 prescribing physicians), is planning an initial launch in Germany as part of a 50‑country operating platform, expects prior‑authorization workflows and notes typical early launch prescription‑to‑infusion times >60 days, and has a Scholar Rock Supports patient program in place. On clinical programs, SAPPHIRE met the Hammersmith endpoint (p=0.019), Phase II FORGE (n=60) has been initiated, Phase II OPAL is enrolling infants/toddlers <2 robustly, SRK‑439 Phase I dosing is ongoing with top‑line data expected later this year, and subcutaneous apitegromab showed favorable PK/PD in January. Financially the company ended Q2 with $492M in cash, cash equivalents and marketable securities (including $63M net ATM proceeds), reported Q2 operating expenses of $108.9M (including $19.7M stock‑based comp; $89.2M ex‑SBC), has a $150M draw option on its debt facility upon approval, and plans to monetize a priority review voucher to further strengthen the balance sheet.Scholar Rock Holding Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 33.19M | 18.82M |
| Gross Profit | -97.70M | -208.44M | -1.94M | -2.84M | -89.85M | -89.65M |
| EBITDA | -396.42M | -369.39M | -237.52M | -162.94M | -129.48M | -129.17M |
| Net Income | -408.59M | -377.94M | -246.29M | -165.79M | -134.50M | -131.80M |
Balance Sheet | ||||||
| Total Assets | 523.54M | 404.27M | 474.92M | 311.04M | 358.17M | 304.44M |
| Cash, Cash Equivalents and Short-Term Investments | 492.09M | 367.56M | 437.28M | 279.94M | 315.36M | 252.99M |
| Total Debt | 203.83M | 108.92M | 65.13M | 61.82M | 69.40M | 84.47M |
| Total Liabilities | 269.76M | 158.78M | 106.29M | 85.82M | 97.93M | 132.37M |
| Stockholders Equity | 253.78M | 245.49M | 368.63M | 225.22M | 260.24M | 172.07M |
Cash Flow | ||||||
| Free Cash Flow | -296.35M | -300.64M | -201.05M | -145.30M | -133.76M | -132.04M |
| Operating Cash Flow | -296.16M | -300.04M | -200.95M | -145.23M | -132.69M | -126.79M |
| Investing Cash Flow | 87.83M | 218.69M | -76.06M | 41.14M | -171.70M | 134.31M |
| Financing Cash Flow | 393.19M | 228.40M | 353.03M | 102.57M | 194.83M | 44.95M |
Scholar Rock Holding Technical Analysis
Positive
47.67
Price Trends
50.04
Positive
48.83
Positive
45.29
Positive
Market Momentum
-0.21
Negative
54.35
Neutral
85.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRRK, the sentiment is Positive. The current price of 47.67 is below the 20-day moving average (MA) of 50.10, below the 50-day MA of 50.04, and above the 200-day MA of 45.29, indicating a bullish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 54.35 is Neutral, neither overbought nor oversold. The STOCH value of 85.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRRK.
Scholar Rock Holding Risk Analysis
Scholar Rock Holding disclosed 70 risk factors in its most recent earnings report. Scholar Rock Holding reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scholar Rock Holding Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $8.25B | -14.15 | -69.59% | ― | ― | 1.28% | |
59 Neutral | $6.14B | -13.55 | -43.98% | ― | -100.00% | -33.88% | |
54 Neutral | $4.00B | -7.39 | -94.56% | ― | ― | -203.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $6.44B | -15.68 | -160.19% | ― | ― | -14.40% | |
51 Neutral | $3.34B | -12.83 | -38.33% | ― | -88.87% | -35.06% | |
47 Neutral | $2.55B | -4.59 | 392.35% | ― | 17.50% | -5.66% |
* Healthcare Sector Average
SRRK
Scholar Rock Holding
51.89
20.43
64.94%
RARE
Ultragenyx Pharmaceutical
26.80
-0.59
-2.15%
VKTX
Viking Therapeutics
34.44
-3.75
-9.82%
XENE
Xenon
64.23
30.12
88.30%
IMVT
Immunovant
39.89
25.13
170.26%
NAMS
NewAmsterdam Pharma Company
27.98
3.61
14.81%
Scholar Rock Holding Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Scholar Rock Expands $200 Million At-The-Market Program
Positive
Aug 6, 2026
On August 6, 2026, Scholar Rock filed a new prospectus supplement with the SEC for its existing at-the-market equity offering program with Jefferies, enabling the company to sell additional common shares with an aggregate offering price of up to $...
Executive/Board ChangesShareholder Meetings
Scholar Rock Shareholders Reaffirm Board, Governance and Oversight
Positive
Jun 5, 2026
At its June 4, 2026 annual meeting, Scholar Rock shareholders elected four Class II directors, including David Hallal, Kristina Burow, Michael Gilman and Katie Peng, to new three-year terms ending in 2029. The voting outcomes underscore continued ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches
Positive
May 7, 2026
Scholar Rock on May 7, 2026 reported first-quarter 2026 results and recent milestones, highlighting FDA acceptance of its Biologics License Application for apitegromab in spinal muscular atrophy with a Sept. 30, 2026 PDUFA action date and ongoing ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.